Programmable lipid nanoparticles for RNA therapeutics: Design principles and clinical translation

  • Talemi, Mahdi Navid
  • Farani, Marzieh Ramezani
  • Eskandani, Naiyereh Alipour
  • Mirzaee, Danial
  • Alipourfard, Iraj
  • ... Huh, Yun Suk
Citations

WEB OF SCIENCE

4
Citations

SCOPUS

4

초록

RNA therapeutics have come of age as clinically validated modalities including mRNA, siRNA, antisense oligonucleotides (ASOs), and in vivo genome editing, with lipid nanoparticles (LNPs) as the main non-viral delivery system. This review defines programmable LNPs as systems whose composition and interfacial chemistry are tuned to control organ tropism, cell specificity, intracellular trafficking, and immune interactions. We summarize design rules across four core components (ionizable lipid, phospholipid, cholesterol, PEG-lipid) and highlight levers like apparent pKa optimization (similar to 6-7 for hepatic delivery), biodegradable linkers, PEG-anchor-dependent shedding, ligands (e.g., GalNAc), and selective organ-targeting (SORT) lipids that redirect biodistribution beyond the liver. We survey advances in data-guided formulation, including DNA-barcoded in vivo libraries, machine learning, and physics-based prediction, plus scalable manufacturing (microfluidics, confined impinging-jet mixing, tangential-flow filtration) and Quality-by-Design with process-analytical technologies. A comprehensive characterization toolkit (size/zeta-potential, cryo-EM/SAXS, RNA encapsulation and integrity, apparent pK(a), in vivo barcoding) maps to critical quality attributes. Applications span vaccines, protein replacement, siRNA/ASO delivery, and CRISPR platforms, with clinical examples like patisiran, COVID-19 and RSV mRNA vaccines, inhuman transthyretin (TTR) editing, and individualized melanoma vaccination. We analyze translational constraints like endosomal escape, reactogenicity and anti-PEG immunity, complement activation, and lot-to-lot control, plus success factors: corona-aware design, dose-efficient potency at low lipid burden, redosing strategies, and fit-for-purpose biomarkers. Together, programmable LNPs offer a generalizable path to extrahepatic, cell-aware RNA medicine when coupled to rigorous analytics and platform manufacturing.

키워드

Lipid nanoparticlesRNA therapeuticsProgrammable delivery systemsIonizable lipidsClinical translationmRNA vaccinesGene editingMESSENGER-RNAHELPER LIPIDSIN-VIVODELIVERYNANOMEDICINESFORMULATIONSQUALITY
제목
Programmable lipid nanoparticles for RNA therapeutics: Design principles and clinical translation
저자
Talemi, Mahdi NavidFarani, Marzieh RamezaniEskandani, Naiyereh AlipourMirzaee, DanialAlipourfard, IrajHuh, Yun Suk
DOI
10.1016/j.mtbio.2026.102774
발행일
2026-04
유형
Article
저널명
MATERIALS TODAY BIO
37